metaEvidence - study list


	Study	study type RCT OBS RCT + OBS	Pathology	T1	T0	Patients	sample sizes	ROB	Results
endometrial cancer endometrial cancer
versus placebo plus SoC
	pembrolizumab plus SoC
	NRG-GY018_pMMR, 2023 NCT03914612	RCT	endometrial cancer	pembrolizumab	placebo	Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer. The patients were stratified into two cohorts according to whether they had mismatch repair–deficient (dMMR) or mismatch repair–proficient (pMMR) disease	295 / 296	low	conclusif	demonstrated 46 % decrease in progression or deaths (PFS) (PE) press realease 03/2024 : OS 0.79 [0.53; 1.17]not indexed in the results due to lack of information on the timepoint for this analysis
	NRG-GY018_dMMR, 2023 NCT03914612	RCT	endometrial cancer	pembrolizumab	placebo	Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer. The patients were stratified into two cohorts according to whether they had mismatch repair–deficient (dMMR) or mismatch repair–proficient (pMMR) disease	112 / 113	low	conclusif	demonstrated 70 % decrease in progression or deaths (PFS) (PE) press realease 03/2024 : OS 0.55 [0.25; 1.19] not indexed in the results due to lack of information on the timepoint for this analysis
versus Standard of Care (SoC)
	pembrolizumab plus lenvatinib
	LEAP-001/ENGOT-en9, 2024 NCT03884101	RCT	endometrial cancer	pembrolizumab plus levitinib	carboplatine plus paclitaxel	First-line Treatment of Advanced or Recurrent Endometrial Carcinoma	-/-	NA	inconclusive	inconclusive 7 % decrease in deaths (OS) (PE) inconclusive 9 % decrease in progression or deaths (PFS) (PE)
	KEYNOTE-775, 2023 New England Journal of Medicine NCT03517449	RCT	endometrial cancer	pembrolizumab plus lenvatinib	Paclitaxel or Doxorubicin	Participants With Advanced recurrent or metastatic Endometrial Cancer. Eligible women had disease progression after the receipt of one previous platinum-based chemotherapy regimen	411 / 416	some concern	conclusif	suggested 35 % decrease in deaths (OS) (PE) demonstrated 44 % decrease in progression or deaths (PFS) (PE) suggested 44 % decrease in PFS (extension)